June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Early effect of dexamethasone intravitreal implant for diabetic macular edema in the clinical setting.
Author Affiliations & Notes
  • Giuseppe Lo Giudice
    Ophthalmology, San Antonio Hospital, Padova, Italy
  • Antonio Avarello
    Ophthalmology, San Antonio Hospital, Padova, Italy
  • Morena Masetto
    Ophthalmology, San Antonio Hospital, Padova, Italy
  • Alessandro Galan
    Ophthalmology, San Antonio Hospital, Padova, Italy
  • Footnotes
    Commercial Relationships Giuseppe Lo Giudice, None; Antonio Avarello, None; Morena Masetto, None; Alessandro Galan, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1770. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Giuseppe Lo Giudice, Antonio Avarello, Morena Masetto, Alessandro Galan; Early effect of dexamethasone intravitreal implant for diabetic macular edema in the clinical setting.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1770.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate the early effect of dexamethasone intravitreal implant (Ozurdex®; Allergan Inc, Irvine, CA, USA) in patients with recalcitrant diabetic macular edema (DME).

Methods: Prospective, non-randomized, interventional clinical series. Patients (n = 20 eyes) with recalcitrant DME, 4 or more months after one or more treatments of macular laser photocoagulation and/or intravitreal anti-vascular endothelial growth factor (VEGF), injections, best-corrected visual acuity (BCVA) of 20/32 to 20/200 Snellen equivalent, and central retinal thickness (CRT) of ≥300 μm by optical coherence tomography (OCT) were recruited. Exclusion criteria included history of corticosteroid-responsive intraocular pressure (IOP) rise, cataract extraction, or other intraocular surgery within 3 months; vitrectomized eyes were also excluded. Patients underwent single implant with Ozurdex® implant 0.7 mg, followed at 3 hours, 3,7, and 30 days after treatment. The main outcome was change in central macular thickness on OCT in response to Ozurdex® injection. Secondary outcome measures included visual acuity and changes in IOP following intravitreal implant.

Results: Mean age of patients was 65 years. Mean duration of diabetes mellitus was 14.4 years. Systemic control of DM as assessed by FBS/PPBS and HbA1c. The pre-operative mean central macular thickness was 744 μm and improved to 626 μm, 470 μm, 325 and 240 μm at 3 hours, 3, 7 and 30-day respectively. Preoperative mean BCVA was 0.6 logMAR units and improved to 0.3 and 0.45 logMAR units at 7 and 30 days, respectively. All patients experienced a controlled IOP after the injection with 2 out of 20 eyes affected by transient increasing IOP during follow-up

Conclusions: Ozurdex® appears efficacious in management of recalcitrant diabetic macular edema with significant improvements in best-corrected visual acuity and central macular thickness from the third hour of implant in DME sufferers, and this improvement was sustained during follow-up.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.